Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07065903 · ClinicalTrials.gov registry record

Nimodipine Variability in SAH

A clinical trial of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage, sponsored by University of Alberta.

Recruiting
Registry status
500
Enrollment target
3
Study locations

NCT07065903 is a study of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 500 participants, above the 101-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (395% higher). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07065903, a study of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage, is actively recruiting participants, sponsored by University of Alberta.

RECRUITING
Registry status
500 participants
Enrollment target
3
Study locations

Study Summary

Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patients during their most productive years. Complications following SAH are common, and they can cause major long-term disability. Only one medication - nimodipine - has been proven to benefit the health and wellbeing of these patients. All SAH patients should receive nimodipine for 21 days at a fixed dose. However, our early work suggested that all patients are not getting equal amounts of nimodipine into their blood. In addition, the two different forms (structural mirror images) of nimodipine might have different effects. Reduced amounts of nimodipine in the blood may lessen its benefit and contribute to worsening health and wellbeing of SAH patients. The overall goal of this research is to see what happens with different nimodipine doses and to confirm whether the two forms of nimodipine have different effects. The investigators will conduct a multi-centre study in adult patients admitted for SAH in Canada and the USA. The investigators will collect blood samples to determine the amount of each type of nimodipine in each participant's body, and then will check to see how each participant is doing at 90 days following SAH. They will also check other factors affecting nimodipine levels, so that they can in the future suggest dose recommendations that are actually tailored to each patient.

Conditions Studied

Subarachnoid Hemorrhage, Aneurysmal Subarachnoid Aneurysm Hemorrhage

Study Locations (3)

Virginia

  • VCU Medical Center - Richmond

Alberta

  • University of Alberta Hospital - Edmonton

Ontario

  • University Health Network - Toronto Western Hospital - Toronto

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-05-13
Est. Completion 2029-09

Sponsor

University of Alberta

19 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07065903

The ClinicalTrials.gov registry entry for NCT07065903 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 101-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (395% higher). The listed sponsor is University of Alberta, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Subarachnoid Hemorrhage, Aneurysmal appearing as the primary indexed condition, and to 0 interventions.

NCT07065903 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Virginia, Alberta, Ontario.

Frequently Asked Questions

What is clinical trial NCT07065903 about?

NCT07065903 is a clinical study titled "Nimodipine Variability in SAH". Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patient...

What is the current status of trial NCT07065903?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-05-13. Estimated completion is 2029-09.

What conditions does trial NCT07065903 study?

This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Aneurysmal, Subarachnoid Aneurysm Hemorrhage.

Who is sponsoring clinical trial NCT07065903?

This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07065903 being conducted?

This trial has 3 study locations across Virginia, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Subarachnoid Hemorrhage, Aneurysmal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Subarachnoid Hemorrhage, Aneurysmal

All registered trials for this condition

Subarachnoid Aneurysm Hemorrhage

All registered trials for this condition

Virginia

All trials with a study site in Virginia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.